NVDA
Nvidia’s AI empire has a biotech chapter
Nvidia’s latest 13F filing didn’t just say, “Hey, we bought some stuff.” It revealed a stake in Generate Biomedicines, a biotech with a very sci-fi-sounding mission: make biology programmable. If that sounds like the plot of a streaming show, welcome to the modern market.
The pitch: more guesses, less hoping
Generate’s co-founder and CTO Gevorg Grigoryan says the company was built on the idea that machine learning can turn biology into something you can actually model, test, and iterate on at scale. In plain English: instead of relying on a few expensive hunches, AI can crank out tons of hypotheses and pressure-test them faster than old-school drug discovery ever could.
That matters because drug development is basically the world’s most expensive game of “maybe.” If AI can raise the odds of finding a real winner, the payoff could be huge — for biotech, for Nvidia, and for anyone trying to monetize the AI boom beyond chatbots and data centers.
Why investors should squint at this
For Nvidia, the stake is another reminder that its AI reach is getting weirdly wide. It’s not just the picks-and-shovels company for training models; it’s also backing the businesses trying to use those models in industries with giant addressable markets.
- More proof the AI money is spreading into healthcare and life sciences
- Another sign Nvidia wants exposure to the apps, not just the infrastructure
- A subtle reminder that 13F filings can reveal where the biggest AI whales are swimming
Big picture: if AI really does start rewriting the rules of drug discovery, today’s stake could look less like a side bet and more like an early ticket to the next big platform shift.